Compliant treatment with anti-copper agents prevents clinically overt Wilson's disease in pre-symptomatic patients

European Journal of Neurology

Volumn 21, Issue 2, 2014, Pages 332-337

  Dziezyc, K ^a   Karlinski M ^a   Litwin, T ^a   Czlonkowska, A ^a,b  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Anti copper treatment; Family screening; Symptom development; Wilson's disease

Indexed keywords

ALBUMIN; CERULOPLASMIN; PENICILLAMINE; ZINC SULFATE;

ALBUMIN BLOOD LEVEL; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CERULOPLASMIN BLOOD LEVEL; DEPRESSION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SURVIVAL RATE; WILSON DISEASE;

ANTI-COPPER TREATMENT; FAMILY SCREENING; SYMPTOM DEVELOPMENT; WILSON'S DISEASE;

ADOLESCENT; ADULT; CHELATING AGENTS; CHILD; FEMALE; FOLLOW-UP STUDIES; HEPATOLENTICULAR DEGENERATION; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PENICILLAMINE; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT; ZINC SULFATE;

EID: 84892486893     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12320     Document Type: Article

References (23)

1. Ala A, Walker AP, Askhan K, Dooley JS, Schilsky ML. Wilson's disease. Lancet 2007; 369: 397-408.
2. Petrukhin K, Fisher SG, Pirustu M, et al. Mapping, cloning and genetic characterization of the region containing the Wilson disease gene. Nature Genet 1993; 5: 338-343.
3. Tanzi RE, Petrukhin K, Chernov I, et al. The Wilson disease gene is copper transporting ATP-ase with homology to the Menkes disease gene. Nature Genet 1993; 5: 344-350.
4. Scheinberg HI, Sternlieb I. Wilson's disease and idiopathic copper toxicosis. Am J Clin Nutr 1996; 63: 842-845.
5. Machado A, Chien HF, Deguti MM, et al. Neurological manifestations in Wilson's disease: report of 119 cases. Mov Disord 2006; 21: 2192-2196.
6. Brewer G. Recognition, diagnosis, and management of Wilson's disease. PSEBM 2000; 223: 39-46.
7. Sternlieb I. Perspectives on Wilson's disease. Hepatology 1990; 12: 234-239.
8. Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int 2003; 23: 139-142.
9. Ferenci P. Review article: diagnosis and current therapy of Wilson's disease. Aliment Pharmacol Ther 2004; 9: 157-165.
10. Walshe JM. Diagnosis and treatment of presymptomatic Wilson's disease. Lancet 1988; 2: 435-437.
11. Sternlieb I, Scheinberg H. Prevention of Wilson's disease in asymptomatic patients. N Engl J Med 1968; 278: 352-359.
12. European Association for Study of the Liver. EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol 2012; 56: 671-685.
13. Ravin HA. An improved colometric assay of ceruloplasmin. J Lab Clin Med 1961; 61: 161-168.
14. Gromadzka G, Schmidt HH, Genschel J, et al. Frameschift and nonsense mutations in the gene for ATPase7B are associated with severe impairment of copper metabolism and with early clinical manifestation of Wilson's disease. Clin Genet 2005; 68: 524-532.
15. Gromadzka G, Schmidt HH, Genschel J, et al. p.H1069Q mutation in ATP7B and biochemical parameters of copper metabolism and clinical manifestation of Wilson's disease. Mov Disord 2006; 21: 245-248.
16. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11: 44-47.
17. Central Statistical Office of Poland. http.//www.stat.gov.pl (accessed 30/06/2012).
18. Roberts E, Schilsky M. Diagnosis and treatment of Wilson's disease: an update. Hepatology 2008; 47: 2089-2111.
19. Ferenci P, Czlonkowska A, Merle U, et al. Late-onset Wilson's disease. Gastroenterology 2007; 132: 1294-1298.
20. Czlonkowska A, Gajda J, Rodo M. Effects of long-term treatment in Wilson's disease with D-penicillamine and zinc sulphate. J Neurol 1996; 243: 269-273.
21. Medici V, Trevisan CP, D'Incà R, et al. Diagnosis and management of Wilson's disease: results of a single center experience. J Clin Gastroenterol 2006; 40: 936-941.
22. Walshe JM. Wilson's disease presenting with features of hepatic dysfunction: a clinical analysis of eighty-seven patients. Q J Med 1989; 70: 253-263.
23. Maselbas W, Chabik G, Czlonkowska A. Perstistence with treatment in patients with Wilson disease. Neurol Neur Pol 2010; 44: 260-263.